Stocks Overview

LAST PRICE
42.5400
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
17.1100/ 1
Ask / Lots
45.9900/ 2
Open / Previous Close
0.0000 / 42.5400
Day Range
---
52 Week Range
Low 31.5200
High 54.9800
Volume
---
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Monday's close: 44.02
Time	Volume	RARE
09:32 ET	2588	43.31
09:34 ET	900	43.645
09:36 ET	100	43.46
09:38 ET	300	43.715
09:43 ET	828	44.22
09:45 ET	300	44.145
09:48 ET	100	44.08
09:50 ET	200	44.25
09:52 ET	200	44.225
09:54 ET	100	44.32
09:56 ET	1614	44.235
09:57 ET	100	44.245
10:01 ET	5810	43.98
10:03 ET	1747	43.92
10:08 ET	200	44.08
10:10 ET	1000	44.15
10:12 ET	600	44.05
10:14 ET	400	44
10:17 ET	412	44.04
10:19 ET	612	43.99
10:21 ET	200	43.94
10:24 ET	742	43.9055
10:26 ET	203	43.95
10:28 ET	200	43.81
10:30 ET	100	43.77
10:32 ET	480	43.75
10:33 ET	100	43.75
10:35 ET	829	43.68
10:37 ET	500	43.89
10:39 ET	100	43.875
10:42 ET	177	43.8962
10:44 ET	1714	43.88
10:46 ET	101	43.7671
10:50 ET	220	43.87
10:51 ET	1000	43.83
10:53 ET	800	43.89
10:55 ET	504	43.94
10:57 ET	500	43.925
11:00 ET	300	43.915
11:02 ET	800	43.905
11:04 ET	1101	44
11:06 ET	1100	43.91
11:08 ET	500	43.95
11:09 ET	100	43.955
11:13 ET	1200	43.925
11:15 ET	400	43.925
11:20 ET	500	43.89
11:22 ET	906	43.88
11:24 ET	1664	43.93
11:26 ET	1080	43.94
11:27 ET	100	43.9
11:29 ET	613	43.85
11:31 ET	600	43.81
11:33 ET	1441	43.89
11:36 ET	631	43.93
11:38 ET	360	43.875
11:40 ET	500	43.89
11:42 ET	400	43.85
11:44 ET	600	43.895
11:45 ET	100	43.915
11:47 ET	200	43.89
11:49 ET	2889	43.79
11:51 ET	1198	43.83
11:54 ET	100	43.835
11:58 ET	850	43.925
12:00 ET	1565	43.8
12:03 ET	1115	43.8325
12:05 ET	400	43.855
12:07 ET	2105	43.81
12:09 ET	500	43.82
12:12 ET	100	43.81
12:14 ET	536	43.835
12:16 ET	100	43.8
12:18 ET	100	43.79
12:20 ET	1600	43.81
12:21 ET	300	43.83
12:23 ET	1400	43.82
12:25 ET	400	43.77
12:27 ET	1040	43.68
12:30 ET	1338	43.71
12:32 ET	1000	43.67
12:34 ET	1300	43.64
12:36 ET	1481	43.62
12:38 ET	507	43.58
12:39 ET	784	43.49
12:41 ET	200	43.48
12:43 ET	1776	43.46
12:45 ET	200	43.47
12:48 ET	100	43.475
12:50 ET	200	43.5
12:52 ET	3060	43.495
12:54 ET	400	43.47
12:56 ET	1200	43.48
01:01 ET	200	43.44
01:03 ET	1236	43.5
01:06 ET	1502	43.47
01:08 ET	714	43.535
01:10 ET	400	43.505
01:12 ET	700	43.54
01:14 ET	500	43.57
01:15 ET	1100	43.58
01:17 ET	1150	43.585
01:19 ET	500	43.6
01:24 ET	1745	43.63
01:26 ET	1024	43.63
01:28 ET	200	43.62
01:32 ET	1200	43.605
01:33 ET	500	43.58
01:35 ET	100	43.58
01:37 ET	494	43.58
01:39 ET	800	43.56
01:42 ET	600	43.55
01:44 ET	200	43.56
01:46 ET	200	43.55
01:48 ET	100	43.55
01:50 ET	300	43.55
01:51 ET	1890	43.5975
01:53 ET	100	43.58
01:55 ET	2623	43.565
01:57 ET	700	43.625
02:00 ET	909	43.61
02:02 ET	500	43.55
02:04 ET	398	43.47
02:06 ET	727	43.44
02:08 ET	500	43.38
02:09 ET	885	43.35
02:11 ET	1200	43.35
02:13 ET	800	43.33
02:15 ET	500	43.32
02:18 ET	400	43.31
02:20 ET	2100	43.29
02:22 ET	4300	43.32
02:24 ET	677	43.41
02:26 ET	300	43.44
02:27 ET	500	43.43
02:29 ET	1536	43.44
02:31 ET	900	43.43
02:33 ET	400	43.44
02:36 ET	400	43.42
02:38 ET	1000	43.44
02:40 ET	400	43.47
02:42 ET	1380	43.485
02:44 ET	300	43.44
02:45 ET	900	43.48
02:47 ET	300	43.445
02:49 ET	755	43.42
02:51 ET	1429	43.41
02:54 ET	700	43.45
02:56 ET	300	43.45
02:58 ET	1300	43.45
03:00 ET	800	43.48
03:02 ET	436	43.51
03:03 ET	816	43.54
03:05 ET	500	43.555
03:07 ET	1832	43.59
03:09 ET	1300	43.61
03:12 ET	900	43.61
03:14 ET	700	43.49
03:16 ET	600	43.46
03:18 ET	849	43.4
03:20 ET	300	43.37
03:21 ET	2805	43.43
03:23 ET	1400	43.31
03:25 ET	1300	43.264
03:27 ET	1848	43.31
03:30 ET	2400	43.32
03:32 ET	1251	43.21
03:34 ET	1261	43.14
03:36 ET	4066	43.15
03:38 ET	3700	43.04
03:39 ET	7650	43.08
03:41 ET	6415	43.06
03:43 ET	3637	43.04
03:45 ET	6428	42.92
03:48 ET	9868	43.01
03:50 ET	7552	43.07
03:52 ET	18280	43.035
03:54 ET	10167	42.92
03:56 ET	28043	42.67
03:57 ET	26793	42.585
03:59 ET	49789	42.54

Data delayed at least 15 minutes.

Yesterday
- Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease, from 14 hours ago by Dow Jones
  14 hours ago by Dow Jones
- Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI), from 22 hours ago by Dow Jones
  22 hours ago by Dow Jones
Apr 25, 2024
- Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update, from 4:30PM ET on Thursday Apr 25, 2024 by Dow Jones
  4:30PM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 24, 2024
- DJ Ultragenyx Pharma Is Maintained at Buy by TD Cowen, from 1:33PM ET on Wednesday Apr 24, 2024 by Dow Jones
  1:33PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 22, 2024
- DJ Ultragenyx Pharma Initiated at Outperform by RBC Capital, from 5:51AM ET on Monday Apr 22, 2024 by Dow Jones
  5:51AM ET on Monday Apr 22, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesRARE Ultragenyx Pharmaceutical Inc	3.5B	-5.1x	---
United StatesFOLD Amicus Therapeutics Inc	3.0B	-19.4x	---
United StatesINSM Insmed Inc	3.7B	-4.6x	---
United StatesAXSM Axsome Therapeutics Inc	3.5B	-14.2x	---
United StatesCRSP CRISPR Therapeutics AG	4.5B	-27.2x	---
United StatesGMAB Genmab A/S	18.6B	29.3x	+22.71%
As of 2024-05-01

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Contact Information

Headquarters: 60 Leveroni CtNOVATO, CA, United States 94949-5746
Phone: 415-483-8800
Fax: 415-483-8810

Executives

Independent Director: Daniel Welch
President, Chief Executive Officer, Director: Emil Kakkis
Chief Financial Officer, Executive Vice President: Howard Horn
Executive Vice President, Chief Technical Operations Officer and Gene Therapy Operations: Dennis Huang
Executive Vice President, Chief Legal Officer, General Counsel: Karah Parschauer

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$3.5B
Revenue (TTM)	$434.2M
Shares Outstanding	82.3M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.68
EPS	$-8.33
Book Value	$3.35
P/E Ratio	-5.1x
Price/Sales (TTM)	8.1
Price/Cash Flow (TTM)	---
Operating Margin	-131.08%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Ultragenyx Pharmaceutical Inc
NASDAQ:RAREUnited States

Search Criteria

Charts

Recent News

Yesterday

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease, from 14 hours ago by Dow Jones

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI), from 22 hours ago by Dow Jones

Apr 25, 2024

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update, from 4:30PM ET on Thursday Apr 25, 2024 by Dow Jones

Apr 24, 2024

DJ Ultragenyx Pharma Is Maintained at Buy by TD Cowen, from 1:33PM ET on Wednesday Apr 24, 2024 by Dow Jones

Apr 22, 2024

DJ Ultragenyx Pharma Initiated at Outperform by RBC Capital, from 5:51AM ET on Monday Apr 22, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar